Lifeward names Josh Hexter interim CEO effective Sept. 1

• Lifeward named Josh Hexter interim CEO effective Sept. 1, 2026, replacing Mark Grant, who will consult through Sept. 30.
• Hexter previously served as chief operating and business officer at Oramed Pharmaceuticals, chief business officer at BrainsWay, and led corporate in-licensing at BioLineRx.
• Rami Aviram was appointed CFO effective Nov. 1, 2026.
• Aviram most recently served as CFO of Beewise; he previously held CFO roles at ENDYMED Medical and senior finance posts at Syneron-Candela.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608311615PRIMZONEFULLFEED9818640) on August 31, 2026, and is solely responsible for the information contained therein.